Skip to main content
Fig. 5 | Journal for ImmunoTherapy of Cancer

Fig. 5

From: Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts

Fig. 5

Human PD-L1, MHC class I and class II expression on MDA-MB-231 tumors excised from hu-CB-BRGS. a, Representative flow cytometric analyses for expression of HLA-A,B,C (MHC class I), HLA-DR (MHC class II) and hPD-L1 in digested tumor cell suspensions. The tumor cells are defined as mCD45-, hCD45-, HLA-A,B,C+, Epcam+. The mouse (mCD45) and human (hCD45) hematopoietic cells serve as negative and positive control, respectively. The MFI of HLA-A,B,C (b), HLA-DR (c) and PD-L1 (d) staining is plotted for each tumor. Expression of HLA molecules is normalized to the positive control stained at the same time. Each dot represents data from a tumor from a humanized mouse that was either untreated (−, black) or treated with nivolumab (+, blue) for 11 or 21 days, as indicated. P-values: * < 0.05

Back to article page